NeoGenomics Quarterly Income Statement
NASDAQ: NEOHealth CarePrecision InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NeoGenomics revenue and earnings
In the quarter ended Jun 30, 2026, NeoGenomics generated $201.7 million in revenue, up 11.2% from the same quarter a year earlier. Net income was $2.2 million, for a net margin of 1.1% versus a median of -14.4% in the prior 5 quarters. Gross margin was 45.6% (up from 42.6%) and operating margin -4.8%.
Diluted earnings per share came in at $0.02.
Summary generated from market data by MetaCap's automated system. Methodology
NeoGenomics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 201.66M | 186.67M | 190.17M | 187.80M | 181.33M | 168.03M | 172.00M | 167.82M | 164.50M | 156.24M | 155.55M | 151.95M |
| Revenue growth (YoY) | +11.21% | +11.09% | +10.56% | +11.90% | +10.23% | +7.55% | +10.57% | +10.44% | +11.97% | +13.86% | +12.15% | +17.99% |
| Cost of Revenue | 109.78M | 105.81M | 106.83M | 107.35M | 104.07M | 94.79M | 94.74M | 92.94M | 92.01M | 90.77M | 87.96M | 89.64M |
| Gross Profit | 91.88M | 80.86M | 83.34M | 80.45M | 77.26M | 73.25M | 77.26M | 74.88M | 72.49M | 65.47M | 67.59M | 62.31M |
| Operating Expenses | 101.65M | 99.11M | 96.76M | 107.46M | 124.89M | 101.07M | 95.66M | 96.08M | 94.44M | 96.04M | 86.16M | 86.51M |
| Research & Development | 10.76M | 9.53M | 9.18M | 8.69M | 9.02M | 10.18M | 7.97M | 7.68M | 7.89M | 7.62M | 7.13M | 5.29M |
| Selling, General & Admin | 90.89M | 89.57M | 86.95M | 91.68M | 95.82M | 90.89M | 85.98M | 87.38M | 85.00M | 86.02M | 77.83M | 79.10M |
| Operating Income | -9.77M | -18.24M | -13.41M | -27.01M | -47.63M | -27.82M | -18.40M | -21.20M | -21.94M | -30.57M | -18.57M | -24.20M |
| Interest Expense | 781.00K | 598.00K | 599.00K | 603.00K | 933.00K | 1.62M | 1.62M | 1.64M | 1.67M | 1.69M | 13.74M | -2.84M |
| Other Income (Expense) | -17.00K | -12.00K | 84.00K | -335.00K | 482.00K | 65.00K | -431.00K | 317.00K | -2.00K | -263.00K | 124.00K | -96.00K |
| Pretax Income | 1.83M | -17.58M | -12.41M | -26.39M | -45.82M | -25.66M | -16.13M | -17.85M | -19.02M | -27.68M | -15.29M | -21.45M |
| Income Tax | -412.00K | -472.00K | -2.52M | 740.00K | -724.00K | 266.00K | -804.00K | -150.00K | -375.00K | -620.00K | -960.00K | -2.94M |
| Net Income | 2.24M | -17.11M | -9.88M | -27.13M | -45.09M | -25.92M | -15.32M | -17.70M | -18.64M | -27.06M | -14.33M | -18.52M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | 0.02 | -0.13 | -0.08 | -0.21 | -0.35 | -0.20 | -0.12 | -0.14 | -0.15 | -0.21 | -0.11 | -0.15 |
| EPS (Diluted) | 0.02 | -0.13 | -0.08 | -0.21 | -0.35 | -0.20 | -0.12 | -0.14 | -0.15 | -0.21 | -0.11 | -0.15 |
| Shares Outstanding (Basic) | 129.63M | 129.17M | — | 128.41M | 127.95M | 127.38M | — | 126.95M | 126.41M | 126.11M | — | 125.69M |
| Shares Outstanding (Diluted) | 130.83M | 129.17M | — | 128.41M | 127.95M | 127.38M | — | 126.95M | 126.41M | 126.11M | — | 125.69M |
| EBITDA | -1.20M | -9.46M | -4.65M | -18.21M | -38.49M | -18.46M | -8.57M | -11.57M | -12.20M | -20.66M | -9.00M | -14.85M |
| Gross Margin | 45.56% | 43.32% | 43.83% | 42.84% | 42.61% | 43.59% | 44.92% | 44.62% | 44.07% | 41.90% | 43.45% | 41.01% |
| Operating Margin | -4.85% | -9.77% | -7.05% | -14.38% | -26.27% | -16.56% | -10.70% | -12.63% | -13.34% | -19.56% | -11.94% | -15.92% |
| Net Margin | 111.00% | -9.16% | -5.20% | -14.45% | -24.87% | -15.43% | -8.91% | -10.55% | -11.33% | -17.32% | -9.21% | -12.19% |
This table shows 12 quarterly periods of NeoGenomics's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NEO's reporting calendar. What is a income statement?